Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up! sits down with Melissa Andel, Principal and Founder of CommonHealth Solutions to take a closer look at the recent CMS guidance on drug price negotiation for 2026.
A rapidly evolving area of interest is digital therapeutics, evidence-based software interventions used to treat, manage, or as an adjunct treatment for various medical conditions. Here are three reasons why you should attend the Virtual AMCP Summit: Deep Dive into Prescription Digital Therapeutics.
April 2023 Legislative & Regulatory Briefing: AMCP Statement on Federal Court Decisions Regarding FDA Approvals; AMCP Submits Comments on the Medicare Drug Price Negotiation Program; The Equitable Community Access to Pharmacist Services Act
is Reintroduced in Congress; AMCP Comments on Preventive Services Under the ACA; AMCP, Pharmacy Organizations Send Joint Request for Telehealth Prescribing of Buprenorphine.
Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up! sits down with Melissa Andel, Principal and Founder of CommonHealth Solutions to take a closer look at the recent CMS guidance on drug price negotiation for 2026.
On March 17, CMS announced an opportunity for the public to comment on the agency’s initial guidance for the Medicare Drug Price Negotiation Program, as required by the Inflation Reduction Act. Given the anticipated impact of the Drug Price Negotiation program on the practice of managed care pharmacy in the United States, AMCP took the opportunity to submit comments on several provisions outlined in CMS’ guidance. AMCP’s comments cover subject areas such as access to the Maximum Fair Price, manufacturer-specific data required for negotiation, evidence about therapeutic alternatives for the selected drug, CMS’ methodology for developing an initial offer, the removal of a drug from the selected drug list, and Part D formulary inclusion of the selected drug.